Hold is the coherent synthesis: 10/05 lesson binds against Underweight, 10/06/07 lessons bind against pre-positioned adds; preserve optionality with defined triggers and time-decay clause.
The 10/05 lesson binds against Underweight (mean-reversion long, not breakdown short, in oversold high-quality low-beta names with multiple prior Underweight windows). The 10/06 ORCL and 10/07 JNJ lessons bind against pre-positioned adds ahead of unresolved binaries. The trader's Hold with $247 stop, volume-filtered bull trigger ($260 close, RSI>50, volume≥7.5M), distribution-confirmed bear trigger ($252.49 close), and post-election time-decay reassessment is the correct architecture. Neither aggressive add at $256 with binary political catalyst and unconfirmed reversal, nor trimming into the 10/05 mean-reversion configuration, is warranted.
| Position | Action |
|---|---|
| Neither bull trigger ($260 close, RSI>50, volume≥7.5M) nor bear trigger ($252.49 close) fires by November 18 | Explicitly choose: (a) tactical trim to Underweight at 15-25%, (b) re-engaged Hold with new structural triggers anchored to post-election price action, or (c) committed Buy on reversal candle at $240-245 with $238 stop |
| Price reaches $240-245 deep-value entry zone | Pre-committed Buy with reversal candle confirmation and $238 hard stop |
| Democratic sweep with drug pricing reform headlines | Be prepared to re-engage at $235-240 with reversal confirmation rather than chase; $247 stop may gap through in single session |
JNJ at $256.48 is a gift, not a warning—a best-in-class compounder at a confirmed technical support zone with accelerating revenue growth, expanding margins, and a forward P/E of 21.2x that doesn't reflect the fundamental inflection underway.
| Indicator | Value | Signal |
|---|---|---|
| close_50_sma | 264.76 | neutral |
| close_200_sma | 240.73 | bullish |
| close_10_ema | 259.99 | bearish |
| macd | -2.78 | bearish |
| macd_signal | -1.16 | bearish |
| macdh | -1.62 | bearish |
| rsi | 38.38 | neutral |
| boll_lb | 252.49 | neutral |
| boll_mb | 264.90 | neutral |
| boll_ub | 277.30 | neutral |
| atr | 5.16 | neutral |
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
When: $252.49 daily close. Requires distribution confirmation before trimming. Do NOT act on in low-volume sessions (<5M shares).
Then: Trim on confirmation with distribution evidence
2025 earnings show a transformative inflection with revenue accelerating, margins expanding, and net income nearly doubling
EV: "+8.6% (target $278 from $256.48)
JNJ's recent price action represents a rolling over from a +25% run, not a coiled spring ready to launch. The combination of a broken momentum regime, doubled leverage from M&A, a 57% Democratic sweep probability 27 days out, a yield underwater to Treasuries, and a 21x forward P/E that prices in perfect execution creates downside asymmetry. The path of least resistance is toward $240.73 (200 SMA), approximately 6% below current levels, not toward the $264.76 resistance above.
EV: -$240.73 (200 SMA test) over 1-3 months, approximately 6% below current price of ~$256. Downside risk-reward is roughly 2-to-1 versus upside resistance at $264.76 (50 SMA). Democratic sweep scenario targets $217-$230.
→ vs conservative: Net debt of $28.2B (doubled from $12.5B) represents growth capital deployed into Intra-Cellular acquisition ($17.5B), not financial stress; operating margin expanded 590bps to 29.2% and free cash flow hit $19.3B
→ vs conservative: 2.07% dividend yield argument versus 4%+ Treasuries is recency bias; JNJ is a Dividend Aristocrat with 60+ consecutive years of increases, and 96% probability of no Fed cuts in 2026 means the relative yield advantage will reverse
→ vs conservative: PEG ratio of 2.67 is distorted upward because TTM GAAP EPS was crushed by Kenvue spin-off accounting and litigation charges that do not recur
→ vs conservative: 57% Democratic sweep joint probability is a known, dated, fully-discounted event at $278 peak; current price 9% lower represents coiled-spring setup, not risk exposure
→ vs conservative: Current ratio of 1.09 is normal for AAA-rated capital-efficient pharma with $24.5B annual operating cash flow; they don't warehouse excess working capital
→ vs neutral: Static 6% downside calculation is incomplete; 200 SMA is rising from $234.55 to $240.73 over 30 sessions, compressing actual downside to ~4% from current levels
→ vs neutral: Symmetric risk/reward framing misses regime-change scenarios; if Republican hold or sweep narrative moderates, implied move materially larger than static 8.6% upside
→ vs neutral: HOLD positions for breakout confirmation (clean close above $260 with RSI above 50) while maintaining existing position and defined stop at $247 — this is predatory patience, not passivity
Support: 252.49 · 250 · 240.73 | Resistance: 277.3 · 270 · 264.76 · 259.99
Technical analysis of JNJ showing a post-rally pullback to key support at the Bollinger lower band ($252.49), with medium-term trend weakening (50 SMA rolled over) but long-term trend intact (above 200 SMA at $240.73). MACD is in bearish regime (line at -2.78, signal -1.16) but histogram contraction suggests momentum deceleration. RSI recovered from oversold (29.57 on 10/05) to 38.38 but failed to reclaim 50. ATR elevated at 5.16 (vs ~4-4.50 pre-pullback). Key levels: resistance at $277.30 (upper band), $264.76 (50 SMA); support at $252.49 (lower band), $240.73 (200 SMA). Recommendation: HOLD for existing positions with stops near $247; await confirmation (close above $259.99 with RSI >50) for new longs.
Market Cap
$618.09 B
Share Price
~$256
52-Week High
$281.07
52-Week Low
$184.66
Beta
0.206
P/E (TTM)
29.72x
Forward P/E
21.19x
PEG Ratio
2.67
P/B
7.27x
EPS (TTM)
$8.63
Forward EPS
$12.10
Dividend Yield
2.07%
Revenue 2021
$79.99 B
Revenue 2022
$79.99 B
Revenue 2023
$85.16 B
Revenue 2024
$88.82 B
Revenue 2025
$94.19 B
Revenue TTM
$97.93 B
Gross Profit 2024
$61.35 B
Gross Profit 2025
$63.94 B
Gross Profit TTM
$66.73 B
Gross Margin 2024
69.1%
Gross Margin 2025
67.9%
Gross Margin TTM
68.1%
Operating Income 2024
$21.25 B
Operating Income 2025
$25.60 B
Operating Margin 2024
23.9%
Operating Margin 2025
27.2%
Operating Margin TTM
29.2%
EBITDA 2024
$24.78 B
EBITDA 2025
$41.06 B
EBITDA TTM
$34.87 B
Net Income 2021
$20.88 B
Net Income 2022
$17.94 B
Net Income 2023
$35.15 B
Net Income 2024
$14.07 B
Net Income 2025
$26.80 B
Net Income TTM
$21.04 B
Diluted EPS 2022
$6.73
Diluted EPS 2023
$13.72
Diluted EPS 2024
$5.79
Diluted EPS 2025
$11.03
Net Margin 2024
15.8%
Net Margin 2025
28.5%
Net Margin TTM
21.5%
R&D 2022
$14.14 B
R&D 2023
$15.09 B
R&D 2024
$17.23 B
R&D 2025
$14.67 B
R&D % of Revenue 2025
15.6%
SG&A 2025
$23.68 B
SG&A % of Revenue 2025
25.1%
Total Assets 2022
$187.38 B
Total Assets 2023
$167.56 B
Total Assets 2024
$180.10 B
Total Assets 2025
$199.21 B
Stockholders Equity 2022
$76.80 B
Stockholders Equity 2023
$68.77 B
Stockholders Equity 2024
$71.49 B
Stockholders Equity 2025
$81.54 B
Total Debt 2022
$39.64 B
Total Debt 2023
$29.33 B
Total Debt 2024
$36.63 B
Total Debt 2025
$47.93 B
Net Debt 2022
$26.75 B
Net Debt 2023
$7.47 B
Net Debt 2024
$12.53 B
Net Debt 2025
$28.22 B
Cash & Equivalents 2025
$19.7 B
Working Capital 2022
$0.5 B
Working Capital 2023
$7.2 B
Working Capital 2024
$5.6 B
Working Capital 2025
$1.5 B
Goodwill & Intangibles 2022
$74.5 B
Goodwill & Intangibles 2023
$70.7 B
Goodwill & Intangibles 2024
$81.8 B
Goodwill & Intangibles 2025
$99.2 B
Current Ratio 2025
1.089
Operating Cash Flow 2022
$21.19 B
Operating Cash Flow 2023
$22.79 B
Operating Cash Flow 2024
$24.27 B
Operating Cash Flow 2025
$24.53 B
Free Cash Flow 2022
$17.19 B
Free Cash Flow 2023
$17.78 B
Free Cash Flow 2024
$18.06 B
Free Cash Flow 2025
$19.31 B
CapEx 2022
$4.01 B
CapEx 2023
$4.54 B
CapEx 2024
$4.42 B
CapEx 2025
$4.83 B
Dividends Paid 2022
$11.68 B
Dividends Paid 2023
$11.77 B
Dividends Paid 2024
$11.82 B
Dividends Paid 2025
$12.38 B
Buybacks 2022
$6.04 B
Buybacks 2023
$5.05 B
Buybacks 2024
$2.43 B
Buybacks 2025
$5.95 B
Acquisitions 2022
$17.65 B
Acquisitions 2024
$15.15 B
Acquisitions 2025
$17.54 B
ROE
25.7%
ROA
8.6%
Debt/Equity
0.59
50-Day Moving Average
$265.40
200-Day Moving Average
$242.40
Strengths
Concerns
Johnson & Johnson delivered a strong 2025 performance with revenue of $94.19B (+6% YoY) and net income of $26.80B, nearly doubling from the prior year as $7.04B in special charges from 2024 did not recur; TTM revenue is tracking at $97.93B (+10% YoY). The company maintains exceptional financial quality with a AAA credit rating, best-in-class free cash flow of $19.31B that fully supports the 2.07% dividend and buyback program, and an expanding operating margin of 29.2%, though the balance sheet shows rising leverage (net debt doubled to $28.22B) and a tight current ratio of 1.089 following significant M&A activity including the $14.6B Intra-Cellular Therapies acquisition. The forward P/E of 21.2x is reasonable given 6-10% growth prospects, but the PEG of 2.67 suggests limited margin of safety at current levels near the 50-day moving average resistance.
Macro: High-for-long rates (96% no-cut probability), no recession (6%), heavy political/geopolitical tail risk with 90%/64% Democratic congressional odds 27 days from election (Nov 4); Gold at $4,131.80 (+0.44%) signals extreme safe-haven bid; Oil at $103 on Trump Iran de-escalation signal; FRED macro series unavailable due to missing API key.